Background: Fluconazole and ketoconazole both have poor minimum inhibitory concentration than voriconazole. Voriconazole had serious side eff ects in oral and intravenous doses. It has poor water solubility. The objective of the study was to prepare and optimize microemulgel of voriconazole for topical delivery. Aim: Formulation, development, and evaluation of voriconazole microemulgel for topical delivery. Methods: Oil and emulsifi ers selected were on the basis of equilibrium solubility study and emulsifi cation property respectively. The pseudo-ternary plot and constrained simplex lattice design were applied for preparation of microemulsions. Microemulsions were subjected to micelle size, zeta potential, polydispersity index, and in vitro study. They were optimized by Design-Expert ® 9.0.3.1 software. Formulation, development, evaluation and optimization of microemulgel were carried out. Microbial assay of an optimized batch of microemulgel was performed.
INTRODUCTION
Fungal skin infection could be due to yeast fungus that causes candidiasis, ringworm, tinea, etc. that live on the skin, hair or nails. The microemulsion is an isotropic mixture of oil, aqueous phase, and emulsifi er sometimes in combination with co-emulsifi er. 1 Microemulsion integrates drug in solubilized form and small sized micelles provide a large interfacial area for drug penetration. Moreover, oil portion helps to improve permeability. 2 Emulgel is a combination of both emulsion and gel. 3 Microemulgel is a combination of both gel and microemulsion. Hydrophilic and hydrophobic both types of drugs are incorporated into microemulgel and have privileged of large surface area for drug absorption. The oil portion acts as penetration enhancer. 4 Topically used microemulgel has a wide range of advantages and stability of microemulsion is increased when it is incorporated in gel. [5] [6] [7] Voriconazole is BCS (biological classifi cation system) class II drug. It has log p (lipophilicity) 1.65, a molecular weight of 349.310 g/mol. It has better MIC (minimum inhibitory concentration) range (0.078-0.5 μG/mL) than fl uconazole (1-64 μG/mL) and ketoconazole (0.002-16 μG/mL) for candida albicans. It has MIC 50 of 0.0313 μG/mL, MIC 90 of 0.0625 μG/mL, and MIC 99 is less than 1 μG/mL for Candida albicans. MIC value is 8 μG/ mL for the fl uconazole-resistant strain of candida. However, voriconazole had various serious side effects in oral and intravenous doses. 
AIM
Formulation, development, and evaluation of voriconazole microemulgel for topical delivery.
MATERIALS AND METHODS
Voriconazole was gift sample received from Astron lab. Ahmadabad, India. Neem oil was purchased from Parker Biotech Pvt. Ltd., Chennai, India. Acrysol™ K-150 (PG-Polyoxyl 40-hydrogenated castor oil) was gift sample from Corel Pharma, Ahmadabad, India. PEG-400 was purchased from Finar Chemicals Ltd, Ahmadabad, India. Carbomer-934P was purchased from SD Fine Chem. (I) Ltd, India. Propylene glycol (PG) was purchased from Molychem, Mumbai, India. Triethanolamine (TEA) was purchased from Merk Specialties Pvt. Ltd., Mumbai, India. Rose water was purchased from Dabur (I) Ltd. Mumbai, India. Nizral ® Cream (the brand of 2% w/w ketoconazole) was purchased from Johnson and Johnson (I) Pvt. Ltd. Blossom™ Active instant Yeast was purchased from Raunak-Eden Enterprises, Thane. Voveran ® Emulgel purchased from Novartis (I) Pvt. Ltd. SHY-NM™Gel (Carbomer gel) purchased from Group Pharmaceuticals Ltd, Malur, India.
PRELIMINARY STUDY
Voriconazole was subjected to scan under UV spectrophotometer (UV-1800/1601, Shimadzu Corp. Japan). The standard curve of it was also prepared in methanol. Antifungal oils were subjected to scan under UV spectrophotometer in methanol. Oils that have no absorbance in between 200-400 nm were selected for equilibrium solubility study. The equilibrium solubility of voriconazole was determined by adding it in excess amount in 1 mL of oil and then the mixture was stirred continuously for 1 h at 50 rpm (revolution per minute) and at 25°C in a shaker bath (Innova 4230, Brunswick Scientifi c, Edison NJ, USA), following attainment of equilibrium. The obtained supernatant was fi ltered through fi lter paper (pore size 11 μ). Spectrophotometric measurement of the fi ltrate was carried out at λ max (wavelength maximum of voriconazole). Solubility study data was used for selection of oil. 8 
PRE-FORMULATION STUDY
The 300 mg of oil was vortexes (Vortex Mixture, Micro Scientifi c works, Delhi, India) with 300 mg of each emulsifi er and subsequently heated at 40°C to form a homogenous mixture. Microemulsifi cation was checked visually by adding 500 mg of the mixture in 50 mL of distilled water. The selected oil-emulsifi er pair from above two steps emulsifi ed with screened co-emulsifi er which was selected on the basis of emulsifi cation property. 9 Pseudo-ternary phase diagram was prepared by Statistica ® 8 using emulsifi er: co-emulsifi er ratio and oil at a different range of the ratio of 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 against the aqueous phase by titration method and formation of spontaneous clear microemulsion was observed visually.
FORMULATION AND DEVELOPMENT OF VORICONAZOLE MICROEMULSION
Seven batches of voriconazole loaded microemulsion in constrained simplex lattice design were prepared. Emulsifi er: co-emulsifi er (X 1 ), oil (X 2 ), and aqueous phase (X 3 ) were considered as independent factors. Micelle Size (MS), polydispersity index (PDI), the time required for more than 90% voriconazole diffused (t 90 ) were taken as dependent variables. The responses for these micro emulsions were subjected to fi t equations of polynomial for constrained simplex lattice design which was predicted results of all possible micro emulsions (Eq. 1). 10 
Y=B

SCREENING OF GELLING AGENT, PENETRATION ENHANCER, AND THEIR CONCENTRATIONS
Different gels were prepared with help of HPMC, Na CMC, sodium alginate, and Carbomer 934P with different concentrations by continuous stirring for a period of 2h. 12 Amongst these gelling agent and its concentration was screened out on basis that gel formed in the least concentration with desired viscosity, which was used for the prospective study. Viscosities were measured using viscometer of Brookfi eld engineering labs. Inc. at 37±1°C, spindle 6, 50 rpm rotation speed for 30 sec of the time interval. Among the chemical penetration enhancer clove oil, olive oil, PG, isopropyl myristate, eucalyptus oil, laurocapram, urea, dimethyl sulfoxide, citric acid, ascorbic acid, acetone, tween 20, oleic acid, Transcutol P ® options were available for use. 13 
VORICONAZOLE-EXCIPIENTS COMPATIBILITY STUDY
A physical mixture of voriconazole and excipients of microemulgel was prepared geometrically. Several drops of this mixture were dropped onto the liquid cell of FTIR-8400 spectrophotometer (Fourier Transform Infra-Red, Shimadzu Corp. Japan), such that no bubbles were trapped and scanned in the range of 400-4000 cm -1 with resolution of 1 cm -1 . 14 FORMULATION AND DEVELOPMENT OF MICROEMULGEL Carbomer 934P was left overnight for gelling; finally, TEA was added to adjust pH 7. The optimized microemulsion was added in carbomer 934P gel phase. Six different batches of microemulgel were prepared on the basis of trial and error.
EVALUATION OF MICROEMULGEL PHYSICAL APPEARANCE
Prepared microemulgels were observed for color, homogeneity, consistency, texture, and pH.
SPREADABILITY MEASUREMENT
To determine spreadability of microemulgel, 0.5 g of microemulgel was placed within the circle of 1 cm diameter premarked on a glass plate over which the second plate was placed and 5 g weight was allowed to rest on an upper glass plate for 5 min. Increase in diameter due to weight was spreadability. 15 
SYNERESIS MEASUREMENT TEST
Upon standing sometimes microemulgel shrinks a bit and little liquid would leak out. It is called syneresis. In this test, microemulgel was kept in a cylindrical plastic tube with a perforated bottom which was covered with fi lter paper (Whatman No. 41). These tubes were then placed in a clinical centrifuge (Remi equipment, Mumbai, India) and centrifuged for 15 min at 1000 rpm. Cylindrical plastic tube and liquid which were separated from microemulgel were weighed. Percentage of syneresis was calculated as per Eq. 
EXTRUDABILITY TEST
The force required for extruding microemulgel from the tube is called extrudability. Extrudability was measured from the aluminum collapsible tube on the application of weight in g required to extrude at least 0.5 cm ribbon of microemulgel in 10 sec. When more quantity is extruded, extrudability is considered to be better. 17 
IN VITRO DIFFUSION
In vitro diffusion was carried out in the same manner as that of the microemulsion. However, 500 mg sample was taken into donor compartment. Time at which voriconazole diffusion was started from microemulgel i.e. lag time (t leg ) was determined by extrapolating linear portion of the cumulative amount penetrate versus time curve to the x-axis. 18 Since there was a possibility of unpredictable alteration in diffusion studies due to penetration property of Parker Neem ® oil, PG and PEG-400 therefore, in order for better approximation of diffusivity of voriconazole diffusion parameter (D⁄h 2 ) was derived from lag time by D⁄h 2 =1⁄(6×t leg ) equation. 19 Voriconazole steady state fl ux permeation rate (J ss ) was calculated by dividing slope of graph linear portion with diffusion cell area in mg/cm 2 min, a permeability coeffi cient (K p ) was calculated by dividing J ss by the initial concentration of voriconazole in donor chamber in cm 2 min -1 . Enhancement ratio (E r ) was calculated as the ratio of J ss to that of Nizral ® cream. The t mic i.e. time required to achieve MIC value was also calculated from an in vitro study.
VORICONAZOLE RELEASE KINETICS STUDY
In vitro release results profi le obtained for all batches of microemulgel were plotted in models of data treatment as zero-order kinetic model, fi rst-order kinetic model, Higuchi's model, Korsmeyer/ Peppa's model, Hixon-Crowell model. 20 
OPTIMIZATION OF MICROEMULGEL
The desirability of each batch of microemulgel was found individually by way of the manual as Eqs. 3, 4 and 5:
overall desirability would be:
The desirability of voriconazole microemulgel, colors, physical appearance, homogeneity, syneresis, voriconazole release kinetic, spreadability, extrudability, and texture parameters was in desired range, so its desirability was considered as 1. The desirability of voriconazole content, diffusion parameter, pH, viscosity, Q 30 , t 90 , t mic , and t leg were derived. Finally, the batch that had the highest desirability was considered as optimized batch. 21 MICROBIAL ASSAY OF OPTIMIZED BATCH OF MICROEMULGEL Ditch plate technique was used for evaluation of fungistatic activity of a microemulgel. 22 Previously prepared Sabouraud's agar dried plates were used. One g of the microemulgel was placed in a ditch cut in the plate. Freshly prepared culture loops of Saccharomyces cerevisiae (ATCC No.9763) were streaked across agar at a right angle from the ditch to the edge of the plate. Nizral ® cream was used for comparison. Negative Control of microemulgel (without voriconazole) was also prepared. After incubation for 72 h at 25°C, fungal growth was observed and % inhibition was measured as per Eq. 6:
where L 1 = total length of the streaked culture, and L 2 = length of inhibition.
ACCELERATED STABILITY STUDY OF OPTIMIZED BATCH OF MICROEMULGEL
Microemulgel was sealed in the ampoule and then placed in a glass bowl containing desiccators prepared from magnesium hydroxide and calcium chloride then a whole closed bowl of glass was placed in an oven at 30±2°C temperature and 70±5% RH (relative humidity) conditions for 1 month. A duplicate sample was withdrawn at 1 month to evaluate their physicochemical parameters. Physical and chemical stability were evaluated. 23, 24 To check the similarity between two in vitro diffusion profi le similarity factor (f 2 ) and dissimilarity factor (f 1 ) were applied. The equation for them are as below Eqs. 7 and 8:
Where, R t = amount of voriconazole released before stability study, W t = optional weight factor, T t = amount of voriconazole released after stability study, n = No. of experimental data.
STATISTICAL ANALYSIS
The study was presented as the mean of three independent variables ± standard deviation (SD) of them for results. Regression analysis, Microsoft excel (Microsoft Excel Worksheet ® , version Professional Plus 2010, Microsoft Corporation, USA) was employed to determine control factors that signifi cantly affect responses for microemulsions. Unpaired Student's t-test with equal variance was performed for the solubility of voriconazole between an optimized batch of microemulsion and water and also for the in vitro diffusion profi le between an optimized batch of microemulgel and Nizral ® cream. The one-way ANOVA was carried out between zones of inhibition of an optimized batch of microemulgel and Nizral ® cream. The differences between data were considered statistically signifi cant at 95% of confi dence level.
RESULTS
Scanning of voriconazole in methanol and methanolate phosphate buffer at pH 6.8, in the range of 200-400 nm and λ max was found to be 256 nm. Among available antifungal oils, neem oil, black till oil, karanja oil, coconut oil and Parker Neem ® oil were found that had no absorbance in between 200-400 nm. Parker Neem ® oil and rose water had the solubility of voriconazole 7.51±0.14 mg/g and 0.33±0.05 mg/g. They were selected as oil and aqueous phase for the preparation of micro emulsion.
Acrysol ™ K-150: PEG-400 in the ratio of 4:1 ratio was selected for pseudo-ternary phase diagram. The concentration range of Acrysol ™ K-150/PEG-400 mixture: 65-80%; Parker Neem ® Oil: 5-20% and rose water 15-30% were selected for constrained simplex lattice design for microemulsion preparation ( Table 1) .
MS was found to be in the range of 10-305 nm with PDI value of 0.49-17.21, and ζ of -3.02-5.03. The t 90 of microemulsion were reported between 5-105 min. The regression analysis lead Eq. 9, 10, and 11: MS=10.22X 1 The extra design check-point had a response of -2.86 mv. The predicted value based on equation was -2.44 mv.
Among all optimized batches of microemulsion ( Table 2) , E12 had the least % bias. The solubility of voriconazole in E12 was 6.96 ± 0.08 mg/g. The micelle size of the E12 batch was 59.8 nm (Fig. 1) . Carbomer 934P was a good gelling agent as compared to the other gelling agents for preparations of microemulgel formulations even in the low concentration range of 0.5-2% w/w.
Voriconazole-excipients physical mixture exhibit main FTIR peaks at 1616.40 cm -1 , 1006.88 cm -1 , and 2903.57 cm -1 . These were characteristic absorption peaks of voriconazole for C-N stretch of triazole (1616.40 cm -1 ), C-F Stretching Bond (1006.88 cm -1 ), and Triazole ring (2914.54 cm -1 ) respectively (Fig. 2) .
The difference between batches of microemulgel was the only change in concentration of PG ( Table 3) . The prepared voriconazole microemulgel formulations were yellow, viscous creamy preparation with a smooth and homogeneous appearance. Percentage synergies were zero for all formulations. Viscosities of batches were found in descending order as M3 ˃ M2 ˃ M1. All gel follow pseudoplastic or shear thinning fl ow behavior. In vitro diffusion release of voriconazole from all microemulgel formulation was ranked in descending order as M3 > M2 > M1. The t 90 of M3, M2, and M1 were 120 min, 210 min, and 300 min respectively. The pH of all formulations was near to 7. The t leg for all formulations were less than 30 sec. M3 batch had overall desirability of 0.974. The other parameters of microemulgels and some marketed brand were reported in Table 4 .
In the microbial assay, percentage zone of inhibition of M3, voriconazole in DMSO (Dimethyl sulfoxide); M3 without voriconazole, DMSO, Nizral ® cream were found to be 37.32±0.63, 27.17±1.09, 10.14±0.63, 0, 26.45±0.63, respectively (Fig. 3) .
After one-month stability study M3 remained as yellow in color, transparent homogenous, no syneresis developed, texture remained smooth, with slightly acidic. For the in vitro, voriconazole release profi le, f 2 , and f 1 were found to be 99.46 and 0.37. J ss , K p , E r , extrudability, spreadability all were slightly decreased but almost identical. Viscosity was improved followed the pseudoplastic fl ow.
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DISCUSSION
Calibration curves for voriconazole showed linear relationships in between concentration range of 5-35 μG/mL in methanol and in methanolate phosphate buffer pH 6.8. pH values of microemulsions had stated that these formulations were acidic due to voriconazole and neem oil, which were not comfortable with skin, so need to formulate in one type of formulation system i.e. gel or emulgel which could be comfortable with skin. Centrifugation of microemulsions stated that these formulations were kinetically stable. 15 Dilution Test of All microemulsions stated that these formulations were thermodynamically stable. 16 Limpidity (percentage transmittance) was showed that these formulations were stable. 17, 18 Small micelles size was anticipated to provide large surface area for enhanced in vivo penetration of voriconazole. It was found from the results that the MS increases signifi cantly as Neem oil concentration increases. Generally, an increase of electrostatic repulsive forces between microemulsion micelles prevents the coalescence. On the contrary, a decrease of electrostatic repulsive forces would cause phase separation. A positive value of ζ could be attributed to high unsaturated or saturated fatty acid content of neem oil. Predicted values based on equations were very close to the observed value for MS, PDI, and ζ. The study was confi rmation of adequacy of the equation as a predictor of MS, PDI, and ζ of the microemulsion. 13 E12 batch had more than 50% of Acrysol ™ K-150, so it was incorporated into a gel in at least in 4:1 ratio of microemulsion: gel for the preparation of microemulgel, because of Acrysol ™ K-150 had sensitivity up to 50% range only, beyond this limit cause irritation to the skin. 25 The statistical analysis concluded that optimized batch of microemulsion increased the solubility of voriconazole as compared to water. Carbomer 934P gel showed higher viscosity as compared to Na CMC, HPMC and sodium alginate gels and pseudo plastic fl ow, so carbomer 934P was selected as the gelling agent for a prospective study. For optimization of the concentration of carbomer 934P, different concentrations of carbomer 934P (0-2%) were tried for gel preparation and gave acceptable physical properties, from a study it was found that carbomer 934P was a good gelling agent as compared to the other gelling agents for preparations of microemulgel formulations even in the low concentration range. It was concluded that in carbomer 934P gel, with an increase in carbomer 934P concentration, the viscosity was increased. Minimum 20,000 cp viscosity was required for effi cient gel preparation and as viscosity was inversely proportional to the release of drug from the gel. The lesser carbomer 934P content the higher would be the voriconazole release from microemulgel, so at least 1% w/w carbomer 934P was used for the preparation of microemulgel.
Citric acid, ascorbic acid, and acetone could not increase penetration as good as PG, while penetration of voriconazole in formulation is directly proportional to concentration of PG, moreover penetration ability of neem oil was dependent over solvent in which it was solubilized 26 and PG solubilized both hydrophilic and hydrophobic penetration enhancers too and it inhibits partition of penetration enhancer in SC, so PG was used as penetration enhancer in concentration of 1-10% w/w or solvent for penetration enhancer for prospective study.
The pH values of all prepared formulation were in range, which was considered acceptable to avoid the risk of irritation upon application to skin because the skin where fungal infection happened had pH in the range of 6 to 6.8. The values of spreadability indicated that the microemulgel was easily spreadable by the minimum amount of shear stress as like Voveran ® Emulgel. Percentage synergizes showed that selection of carbomer 934P as the gelling agent and at least 1% w/w concentration was appropriated for the preparation of microemulgel of voriconazole.
As the concentration of carbomer 934P was constant in all preparations, the viscosity of all microemulgel was almost the same but the addition of PG increased the viscosity of microemulgel. The values of extrudability indicated that microemulgel was easy to extrude from the collapsible tube like SHY-NM ™ Gel. Proper in vitro diffusion release of voriconazole from all microemulgel formulation was observed.
J ss , K p , E r , were higher, while T 90 , t mic , t leg , % dislodgeable dose after 4 h were lowest with respect to Nizral ® cream in the case of M3 than M2 and M1. These were because of the presence of PG 10%, 5%, and 0%, respectively, which increased penetration of voriconazole from the membrane by a synergistic penetrating effect with neem oil. Microemulgel provided both intracellular diffusion and intercellular penetration of voriconazole, while Nizral ® cream had a penetration of ketoconazole due to intracellular diffusion only. 27 The sum of the square of residual value found to be least in Korsmeyer-Peppas Model so it was predicted that microemulgel followed KorsmeyerPeppas model of kinetics. Release kinetic study followed anomalous transport and rate as function of time were t n-1 because PG as penetration enhancer in microemulgel. 28 The statistical analysis concluded that in vitro voriconazole diffusion was signifi cantly higher than ketoconazole of Nizral ® cream. 29 The study demonstrated that there was significant difference between the zones of inhibition of an optimized batch of microemulgel (M3) and Nizral ® cream (p ˂ 0.05). The probable reason for that was the synergistic action of voriconazole and Neem oil in the M3.
M3 would be stable when packed in a proper container and stored in cool and dry place. The shelf-life was predicted to be 2 years with storage condition at the cool and dry place. In vitro diffusion profi le before and after results indicated that voriconazole diffusion of the formulation before stability and after one-month stability studies was identical and superimposable. 28 In limitations of the study, for example, the microemulgel was not validated for in vivo study. The micro analyst and microbiologist selected for MS, MSD, and microbial assay were not blind for the study.
CONCLUSION
The investigation on voriconazole microemulgel concluded that microemulgel successfully increased the solubility of voriconazole and permeability across stratum corneum. They were characterized, found safe and effective than Nizral ® cream. Moreover, it had shelf-life of 2 years with patient compliance features. This investigation was also validated for physical parameters against SHY-NM ™ Gel and Voveran ® emulgel. 
